Event submissions
The prognosis for patients with GBM remains poor and novel therapeutic approaches to address this unmet clinical need are urgently required. In this work we will present our recent efforts to develop compounds to target and tackle gliomas. Furthermore, we will illustrate other approaches that we are following to develop novel theranostic compounds that could be able to target the specific tumor microenvironment.